Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

By Alan L. Whone, R. Watts, A. Stoessl, Margaret J. Davis, S. Reske, C. Nahmias, A. Lang, O. Rascol, M. Ribeiro, P. Remy and 3 more. Annals of Neurology, 2003

860 citations recorded by the source corpus.

Subfields: Neurology

View Paper: https://www.semanticscholar.org/paper/55305b4d3a7cc4148b8a182cae3cab9cc63717b2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. D. Dexter
2. P. Jenner
3. M. Mouradian
4. V. Dias
5. E. Junn
6. A. Schapira
7. Eduardo Tolosa
8. Kailash Bhatia

Citations in the corpus

• The Role of Oxidative Stress in Parkinson’s Disease (2013, background): “…clinical trials using the dopamine agonists ropinirole and pramipexole, no significant advantage was seen in slowing progression of motor symptoms although imaging studies suggested a benefit of the agonists over L-dopa [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425].”
• Missing pieces in the Parkinson's disease puzzle (2010, background): “Despite these limitations, some Parkinson's disease neuroprotection trials—pramipexole and ropinirole versus levodop”
• Parkinson disease: from pathology to molecular disease mechanisms. (2013, result): “The dopamine agonists ropinirole and pramipexole show neuroprotective actions in preclinical models of PD of dopaminergic cell loss, but in clinical trial (REAL-PET; the Comparison of the Agonist Pramipexole versus Levodopa on Motor Complications of Parkinson’s Disease—CALM-PD) there was no slowing ”
• The role of DAT-SPECT in movement disorders (2008, background): “F]dopa PET imaging as a surrogate marker of disease progression where 5.7–14.7% of the cases clinically diagnosed as early PD had “scans without evidence of dopaminergic deficit” (SWEEDs).”